{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:25:40Z","timestamp":1778898340376,"version":"3.51.4"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.bbi.2019.04.013","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T03:15:40Z","timestamp":1554261340000},"page":"326-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Behavioral conditioning of anti-proliferative and immunosuppressive properties of the mTOR inhibitor rapamycin"],"prefix":"10.1016","volume":"79","author":[{"given":"Laura","family":"L\u00fcckemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meike","family":"Unteroberd\u00f6rster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elian","family":"Martinez Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Schedlowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hadamitzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.bbi.2019.04.013_b0005","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0889-1591(02)00067-3","article-title":"Conditioned immunomodulation: research needs and directions","volume":"17","author":"Ader","year":"2003","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2019.04.013_b0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00006842-197507000-00007","article-title":"Behaviorally conditioned immunosuppression","volume":"37","author":"Ader","year":"1975","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.bbi.2019.04.013_b0015","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.7063864","article-title":"Behaviorally conditioned immunosuppression and murine systemic lupus erythematosus","volume":"215","author":"Ader","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.bbi.2019.04.013_b0020","first-page":"263","article-title":"Conditioning of the immune response","volume":"39","author":"Ader","year":"1991","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.bbi.2019.04.013_b0025","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1073\/pnas.0912344107","article-title":"Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production","volume":"107","author":"Alain","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbi.2019.04.013_b0030","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/clpt.2014.75","article-title":"Preserving learned immunosuppressive placebo response: perspectives for clinical application","volume":"96","author":"Albring","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbi.2019.04.013_b0035","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.98.1.136","article-title":"A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt","volume":"98","author":"Aoki","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbi.2019.04.013_b0040","doi-asserted-by":"crossref","first-page":"539","DOI":"10.7164\/antibiotics.31.539","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation","volume":"31","author":"Baker","year":"1978","journal-title":"J. Antibiot."},{"key":"10.1016\/j.bbi.2019.04.013_b0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.neuropharm.2014.12.008","article-title":"Neurobehavioral consequences of small molecule-drug immunosuppression","volume":"96","author":"Bosche","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbi.2019.04.013_b0050","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1073\/pnas.79.2.583","article-title":"Behaviorally conditioned suppression of a graft-versus-host response","volume":"79","author":"Bovbjerg","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbi.2019.04.013_b0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4049\/jimmunol.132.1.111","article-title":"Acquisition and extinction of conditioned suppression of a graft-vs-host response in the rat","volume":"132","author":"Bovbjerg","year":"1984","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbi.2019.04.013_b0060","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1749-6632.1987.tb35818.x","article-title":"Conditioned suppression of plaque-forming cell responses with cyclophosphamide. The role of taste aversion","volume":"496","author":"Bovbjerg","year":"1987","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.bbi.2019.04.013_b0065","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbi.2019.04.013_b0070","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4161\/oxim.3.6.14787","article-title":"Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders","volume":"3","author":"Chong","year":"2010","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.bbi.2019.04.013_b0075","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.brainresbull.2008.03.005","article-title":"Antidepressive-like effects of rapamycin in animal models: implications for mTOR inhibition as a new target for treatment of affective disorders","volume":"76","author":"Cleary","year":"2008","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bbi.2019.04.013_b0080","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nrn1705","article-title":"Placebos and painkillers: is mind as real as matter?","volume":"6","author":"Colloca","year":"2005","journal-title":"Nat. Rev."},{"key":"10.1016\/j.bbi.2019.04.013_b0085","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","article-title":"mTOR signaling and drug development in cancer","volume":"7","author":"Dancey","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbi.2019.04.013_b0090","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1749-6632.2001.tb05827.x","article-title":"Cytokine-induced sickness behavior: mechanisms and implications","volume":"933","author":"Dantzer","year":"2001","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.bbi.2019.04.013_b0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/brbi.2000.0613","article-title":"Cytokine-induced sickness behavior: where do we stand?","volume":"15","author":"Dantzer","year":"2001","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2019.04.013_b0100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: when the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbi.2019.04.013_b0105","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tips.2011.12.001","article-title":"Utilizing placebo mechanisms for dose reduction in pharmacotherapy","volume":"33","author":"Doering","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbi.2019.04.013_b0110","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuron.2008.06.030","article-title":"New insights into the placebo and nocebo responses","volume":"59","author":"Enck","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.bbi.2019.04.013_b0115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3923","article-title":"The placebo response in medicine: minimize, maximize or personalize?","volume":"12","author":"Enck","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbi.2019.04.013_b0120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0165-5728(98)00122-2","article-title":"Behaviorally conditioned immunosuppression using cyclosporine A: central nervous system reduces IL-2 production via splenic innervation","volume":"88","author":"Exton","year":"1998","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbi.2019.04.013_b0125","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1034\/j.1600-065x.2001.1840120.x","article-title":"Conditioning in the rat: an in vivo model to investigate the molecular mechanisms and clinical implications of brain-immune communication","volume":"184","author":"Exton","year":"2001","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bbi.2019.04.013_b0130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-5728(02)00249-7","article-title":"Behaviorally conditioned immunosuppression in the rat is regulated via noradrenaline and \u03b2-adrenoceptors","volume":"131","author":"Exton","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbi.2019.04.013_b0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-5728(02)00249-7","article-title":"Behaviorally conditioned immunosuppression in the rat is regulated via noradrenaline and h-adrenoceptors","volume":"131","author":"Exton","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbi.2019.04.013_b0140","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fimmu.2012.00312","article-title":"All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells","volume":"3","author":"Gamper","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbi.2019.04.013_b0145","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbi.2019.04.013_b0150","doi-asserted-by":"crossref","first-page":"pe24","DOI":"10.1126\/scisignal.267pe24","article-title":"The pharmacology of mTOR inhibition","volume":"2","author":"Guertin","year":"2009","journal-title":"Sci. Signal"},{"key":"10.1016\/j.bbi.2019.04.013_b0155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbr.2014.06.056","article-title":"Acute systemic rapamycin induces neurobehavioral alterations in rats","volume":"273","author":"Hadamitzky","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbi.2019.04.013_b0160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbi.2015.09.009","article-title":"Memory-updating abrogates extinction of learned immunosuppression","volume":"52","author":"Hadamitzky","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2019.04.013_b0165","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/ijnp\/pyy017","article-title":"Repeated systemic treatment with rapamycin affects behavior and amygdala protein expression in rats","volume":"21","author":"Hadamitzky","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbi.2019.04.013_b0170","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0149-7634(88)80004-6","article-title":"Biological basis of the behavior of sick animals","volume":"12","author":"Hart","year":"1988","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bbi.2019.04.013_b0175","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neuroscience.2012.04.011","article-title":"Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy","volume":"215","author":"Huang","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbi.2019.04.013_b0180","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bbi.2017.01.017","article-title":"Interleukin-1 signaling in the basolateral amygdala is necessary for heroin-conditioned immunosuppression","volume":"62","author":"Hutson","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2019.04.013_b0185","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1073\/pnas.1720548115","article-title":"Learned immunosuppressive placebo responses in renal transplant patients","volume":"115","author":"Kirchhof","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbi.2019.04.013_b0190","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1037\/0735-7044.97.4.663","article-title":"Pavlovian conditioning of immunosuppression modifies adjuvant arthritis in rats","volume":"97","author":"Klosterhalfen","year":"1983","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.bbi.2019.04.013_b0195","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1749-6632.1987.tb35815.x","article-title":"Classically conditioned effects of cyclophosphamide on white blood cell counts in rats","volume":"496","author":"Klosterhalfen","year":"1987","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.bbi.2019.04.013_b0200","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0889-1591(88)90022-0","article-title":"Behaviorally conditioned suppression of mitogen-induced proliferation and immunoglobulin production: effect of time span between conditioning and reexposure to the conditioning stimulus","volume":"2","author":"Kusnecov","year":"1988","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2019.04.013_b0205","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ceb.2009.01.016","article-title":"Optimal targeting of the mTORC1 kinase in human cancer","volume":"21","author":"Lane","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.bbi.2019.04.013_b0210","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bbi.2015.09.005","article-title":"Pre-exposure to the unconditioned or conditioned stimulus does not affect learned immunosuppression in rats","volume":"51","author":"L\u00fcckemann","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2019.04.013_b0215","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.nlm.2017.02.012","article-title":"Applications and limitations of behaviorally conditioned immunopharmacological responses","volume":"142","author":"L\u00fcckemann","year":"2017","journal-title":"Neurobiol. Learn Mem."},{"key":"10.1016\/j.bbi.2019.04.013_b0220","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1741-7015-10-66","article-title":"Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways","volume":"10","author":"Maes","year":"2012","journal-title":"BMC Med."},{"key":"10.1016\/j.bbi.2019.04.013_b0230","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1182\/blood-2008-02-137430","article-title":"Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells","volume":"112","author":"Ohtani","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbi.2019.04.013_b0235","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.trim.2011.07.005","article-title":"Effects of immunosuppressive therapy after experimental small bowel transplantation in rats","volume":"25","author":"Pech","year":"2011","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.bbi.2019.04.013_b0240","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/00006842-197611000-00009","article-title":"Behaviorally conditioned immunosuppression: replication of a recent study","volume":"38","author":"Rogers","year":"1976","journal-title":"Psychosomatic Med."},{"key":"10.1016\/j.bbi.2019.04.013_b0245","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1124\/pr.114.009423","article-title":"Neuro-bio-behavioral mechanisms of placebo and nocebo responses: implications for clinical trials and clinical practice","volume":"67","author":"Schedlowski","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbi.2019.04.013_b0250","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a central controller of cell growth","volume":"103","author":"Schmelzle","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.bbi.2019.04.013_b0255","doi-asserted-by":"crossref","first-page":"13780","DOI":"10.1073\/pnas.93.24.13780","article-title":"TOR2 is required for organization of the actin cytoskeleton in yeast","volume":"93","author":"Schmidt","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbi.2019.04.013_b0260","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.bbi.2019.04.013_b0265","doi-asserted-by":"crossref","first-page":"727","DOI":"10.7164\/antibiotics.28.727","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization","volume":"28","author":"Sehgal","year":"1975","journal-title":"J. Antibiot."},{"key":"10.1016\/j.bbi.2019.04.013_b0270","first-page":"3504","article-title":"A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells","volume":"60","author":"Sekulic","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbi.2019.04.013_b0275","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbr.2011.02.021","article-title":"Favoured genetic background for testing anxiolytics in the fear-potentiated and light-enhanced startle paradigms in the rat","volume":"221","author":"Steiner","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbi.2019.04.013_b0280","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/1440-1681.12601","article-title":"Anorexic response to rapamycin does not appear to involve a central mechanism","volume":"43","author":"Toklu","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.bbi.2019.04.013_b0285","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"Vezina","year":"1975","journal-title":"J. Antibiot."},{"key":"10.1016\/j.bbi.2019.04.013_b0290","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.immuni.2008.08.012","article-title":"The TSC-mTOR signaling pathway regulates the innate inflammatory response","volume":"29","author":"Weichhart","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.bbi.2019.04.013_b0295","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.bbi.2011.05.011","article-title":"Repeated recall of learned immunosuppression: evidence from rats and men","volume":"25","author":"Wirth","year":"2011","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2019.04.013_b0300","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/j.1552-4604.1997.tb04318.x","article-title":"Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration","volume":"37","author":"Zimmerman","year":"1997","journal-title":"J. Clin. Pharmacol."}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159118311590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159118311590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:58:48Z","timestamp":1760169528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159118311590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":59,"alternative-id":["S0889159118311590"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2019.04.013","relation":{},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Behavioral conditioning of anti-proliferative and immunosuppressive properties of the mTOR inhibitor rapamycin","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2019.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}